OLD Dominion Capital Management Inc. cut its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 1.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,120 shares of the medical research company’s stock after selling 88 shares during the period. Thermo Fisher Scientific comprises approximately 1.1% of OLD Dominion Capital Management Inc.’s investment portfolio, making the stock its 20th biggest holding. OLD Dominion Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $1,068,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Schwab Charles Investment Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 9.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 1,537,059 shares of the medical research company’s stock valued at $268,171,000 after purchasing an additional 135,068 shares during the last quarter. Wetherby Asset Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 13.0% in the second quarter. Wetherby Asset Management Inc. now owns 6,169 shares of the medical research company’s stock valued at $1,076,000 after purchasing an additional 711 shares during the last quarter. Bright Rock Capital Management LLC raised its holdings in shares of Thermo Fisher Scientific by 200.0% in the second quarter. Bright Rock Capital Management LLC now owns 42,000 shares of the medical research company’s stock valued at $7,328,000 after purchasing an additional 28,000 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of Thermo Fisher Scientific by 56.3% in the second quarter. Canada Pension Plan Investment Board now owns 435,761 shares of the medical research company’s stock valued at $76,027,000 after purchasing an additional 156,962 shares during the last quarter. Finally, Arrow Financial Corp raised its holdings in shares of Thermo Fisher Scientific by 288.0% in the second quarter. Arrow Financial Corp now owns 2,328 shares of the medical research company’s stock valued at $406,000 after purchasing an additional 1,728 shares during the last quarter. Institutional investors own 83.36% of the company’s stock.

A number of analysts have recently issued reports on TMO shares. Bank of America Corporation reiterated a “buy” rating and issued a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Citigroup Inc. reiterated a “buy” rating and issued a $201.00 price objective (up from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, Deutsche Bank AG set a $200.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Saturday, June 10th. Two analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $193.56.

COPYRIGHT VIOLATION NOTICE: “OLD Dominion Capital Management Inc. Sells 88 Shares of Thermo Fisher Scientific Inc (TMO)” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/20/old-dominion-capital-management-inc-sells-88-shares-of-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Inc (NYSE TMO) opened at 189.62 on Wednesday. The firm’s 50-day moving average is $181.07 and its 200-day moving average is $171.15. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $194.30. The company has a market capitalization of $73.97 billion, a PE ratio of 33.03 and a beta of 1.05.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. Thermo Fisher Scientific’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.03 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

In other news, Director C Martin Harris sold 360 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the sale, the director now directly owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the sale, the director now directly owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,738 shares of company stock valued at $4,021,512. Insiders own 0.49% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.